news
Priority Review granted to pemigatinib for treatment of cholangiocarcinoma
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
List view / Grid view
cholangiocarcinoma
Filter the results
article
The 10 latest FDA Orphan Drug Designations for cancer treatments
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.